Vividion Secures $82 Million to Advance Its Lead Programs into the Clinic
Vividion Therapeutics snagged $82 million in an oversubscribed Series B funding round to bolster its cash holdings that will be used to advance the San Diego-based company’s lead programs into the clinic and broaden the early-stage pipeline of therapeutics against previously intractable drug targets. The latest financing round comes a little more than a year after the company secured $101 million from Celgene last year to develop unique small molecule therapies for a range of